Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTX-474 in Diffuse Cutaneous Systemic Sclerosis
NCT07287670Phase 2Recruiting
- Sponsor
- Mediar Therapeutics
- Start
- Apr 2026
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in diffuse cutaneous systemic sclerosis (dcSSc) comparing MTX-474 with Placebo (2 arms). Primary endpoint: Modified Rodnan Skin Score at 24 weeks. Started Apr 2026; status: recruiting.
02
Drugs
MTX-474
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NCT07287670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07287670.